Matthew Gantz is an entrepreneur.  He served as Executive Vice President for U.S. operations with the global specialty pharmaceutical company BTG International from 2009 until mid-2016. In that role, he had responsibility for BTG’s global specialty pharmaceuticals business and administrative oversight for U.S. business operations. He is a non-executive director of Swedish Orphan Biovitrum. Prior to BTG, Matthew was Founder and CEO of Acureon Pharmaceuticals, a specialty pharmaceutical company focused in the hospital areas of infectious diseases, transplant and ICU. Prior to Acureon, he was the President and CEO of Hydrabiosciences Inc., a privately held biotechnology company developing novel, ion channel medicines in the pain and cardiovascular area. From 2000 to 2003, Matthew was the VP Europe for Chiron’s Biopharmaceutical Division where he was directly responsible for $100+ million Infection Disease and Oncology business. From 1996 to 2000 he was the GM for PathoGenesis Europe before the company was acquired by Chiron. Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew served as an infantry officer in the U.S. Marine Corps, earned his MBA from Harvard and his undergraduate degree from Princeton University.  Matthew served as a company commander and infantry officer in the Marine Corps. His distinguished service during Operation Desert Storm earned him the Navy Commendation Medal with Combat V for “heroic service and courageous leadership under enemy fire.